Shire accepts €52.4bn takeover bid by Takeda

by Biotech Newsroom


The takeover of Shire is the largest acquisition in Takeda’s history. Under the agreement, Takeda will pay  US$66, per share US$30.33 in cash and 0.839 Takeda shares for each Shire share. Takeda will will partly finance the acquisition through a US$30.85bn (€25.56bn) debt from J.P. Morgan Chase, Sumitomo Mitsui, MUFG Bank. The transaction is expected to close in 1H19.

Takeda shareholders will own approximately 50% of the new company, which will be headquartered in Tokyo, where it will maintain its listing and additionally list its American depositary shares (ADS) on NYSE.  The companies expect to save about US$1.4bn in annual costs, mainly…



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC